Page 116 - 南京医科大学自然版

第45卷第1期
·110 · 南 京 医 科 大 学 学 报 2025年1月

membrane antigen，in patients with metastatic prostate 2022，49（8）：2774-2785
cancer［J］. J Nucl Med，2012，53（12）：1883-1891 ［42］HE J，ZHONG Y P，ZHANG S. Technetium⁃99m⁃methy⁃
［32］HARMON S A，BERGVALL E，MENA E，et al. A pro⁃ lene diphosphonate single photon emission computed to⁃
18
spective comparison of F ⁃ sodium fluoride PET/CT and mography/computed tomography combined with prostate⁃
18
PSMA⁃targeted F⁃DCFBC PET/CT in metastatic prostate specific antigen/free prostate ⁃ specific antigen ratio for
cancer［J］. J Nucl Med，2018，59（11）：1665-1671 bone metastasis of prostate cancer［J］. World J Clin Cas⁃
［33］OPREA⁃LAGER D E，GONTIER E，GARCÍA⁃CAÑAM⁃ es，2024，12（20）：4082-4090
18
18
AQUE L，et al.［ F］DCFPyL PET/CT versus［ F］fluoro⁃ ［43］REINFELDER J，KUWERT T，BECK M，et al. First expe⁃
methylcholine PET/CT in biochemical recurrence of pros⁃ rience with SPECT/CT using a 99m Tc⁃labeled inhibitor for
tate cancer（PYTHON）：a prospective，open label，cross⁃ prostate⁃specific membrane antigen in patients with bio⁃
over，comparative study［J］. Eur J Nucl Med Mol Imag⁃ chemical recurrence of prostate cancer［J］. Clin Nucl
ing，2023，50（11）：3439-3451 Med，2017，42（1）：26-33
18
［34］LI Y，WANG S，ZHAO S，et al. Initial［ F］DCFPyL PET/ ［44］BEZVERKHNIAIA E，KANELLOPOULOS P，ABOUZA⁃
CT in treatment ⁃ naïve prostate cancer：correlation with YED A，et al. Preclinical evaluation of a novel high⁃affini⁃
99m
post⁃ADT PSA outcomes and recurrence［J］. Eur J Nucl ty radioligand［ Tc］Tc⁃BQ0413 targeting prostate⁃specif⁃
Med Mol Imaging，2024，51（8）：2458-2466 ic membrane antigen（PSMA）［J］. Int J Mol Sci，2023，24
［35］CARDINALE J，SCHAFER M，BENESOVA M，et al. Pre⁃ （24）：17391
18
clinical evaluation of F⁃PSMA⁃1007，a new prostate⁃ ［45］SCHUCHARDT C，ZHANG J，KULLKARNI H R，et al.
specific membrane antigen ligand for prostate cancer Prostate ⁃ specific membrane antigen radioligand therapy
imaging［J］. J Nucl Med，2017，58（3）：425-431 using 177 Lu⁃PSMA I&T and 177 Lu⁃PSMA⁃617 in patients
［36］MOOKERJI N，PFANNER T，HUI A，et al. Fluorine⁃18 with metastatic castration⁃resistant prostate cancer：com⁃
prostate⁃specific membrane antigen⁃1007 PET/CT vs mul⁃ parison of safety，biodistribution，and dosimetry［J］. J Nu⁃
tiparametric MRI for locoregional staging of prostate can⁃ cl Med，2022，63（8）：1199-1207
cer［J］. JAMA Oncol，2024，10（8）：1097-1103 ［46］ZHA Z，CHOI S R，LI L，et al. New PSMA⁃targeting li⁃
［37］LI T，XU M，YANG S，et al. Development and validation of gands：transformation from diagnosis（Ga⁃68）to radionu⁃
18
［ F］⁃PSMA⁃1007 PET⁃based radiomics model to predict clide therapy（Lu⁃177）［J］. J Med Chem，2022，65（19）：
biochemical recurrence ⁃ free survival following radical 13001-13012
177
prostatectomy［J］. Eur J Nucl Med Mol Imaging，2024，51 ［47］WEN X，XU P，ZENG X，et al. Development of［ Lu］Lu⁃
（9）：2806-2818 LNC1003 for radioligand therapy of prostate cancer with
［38］ZHA Z，CHOI S R，PLOESSL K，et al. Radiolabeling opti⁃ a moderate level of PSMA expression［J］. Eur J Nucl Med
mization and preclinical evaluation of the new PSMA im⁃ Mol Imaging，2023，50（9）：2846-2860
aging agent［ F］AlF⁃P16⁃093［J］. Bioconjug Chem，2021， ［48］BIDKAR A P，ZEREFA L，YADAV S，et al. Actinium⁃225
18
32（5）：1017-1026 targeted alpha particle therapy for prostate cancer［J］.
［39］ZHAO R，KE M，LV J，et al. First⁃in⁃human study of PS⁃ Theranostics，2024，14（7）：2969-2992
18
MA⁃targeting agent，［ F］AlF⁃P16⁃093：dosimetry and ini⁃ ［49］REISSIG F，ZARSCHLER K，NOVY Z，et al. Modulating
tial evaluation in prostate cancer patients［J］. Eur J Nucl the pharmacokinetic profile of actinium⁃225⁃labeled mac⁃
Med Mol Imaging，2024，51（6）：1753-1762 ropa⁃derived radioconjugates by dual targeting of PSMA
［40］ZHAO R，XIA Z，KE M，et al. Determining the optimal and albumin［J］. Theranostics，2022，12（17）：7203-7215
pharmacokinetic modelling and simplified quantification ［50］BUSSLINGER S D，TSCHAN V J，RICHARD O K，et al.
18
225
method of［ F］AlF⁃P16⁃093 for patients with primary pros⁃ ［ Ac］Ac⁃SibuDAB for targeted alpha therapy of prostate
tate cancer（PPCa）［J］. Eur J Nucl Med Mol Imaging， cancer：preclinical evaluation and comparison with［ Ac］
225
2024，51（7）：2124-2133 Ac⁃PSMA⁃617［J］. Cancers，2022，14（22）：5651
［41］WU Y，ZHANG X，ZHOU H，et al. Synthesis，preclinical ［收稿日期］ 2024-08-26
18
evaluation，and first⁃in⁃human study of Al F⁃PSMA⁃Q for （本文编辑：唐 震）
prostate cancer imaging［J］. Eur J Nucl Med Mol Imaging，